2. Academic Validation
  3. BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies

BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies

  • Cancers (Basel). 2022 Aug 23;14(17):4067. doi: 10.3390/cancers14174067.
Pei-Pei Wang 1 2,  Chen Lin 2,  Jane Wang 3,  Georgios Antonios Margonis 4,  Bin Wu 2
Affiliations

Affiliations

  • 1 Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
  • 2 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China.
  • 3 Department of Surgery, University of California San Francisco, San Francisco, CA 94158, USA.
  • 4 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
PMID: 36077604 DOI: 10.3390/cancers14174067
Abstract

Surgery combined with chemotherapy and precision medicine is the only potential treatment for patients with colorectal Cancer liver metastases (CRLM). The use of modern molecular biotechnology to identify suitable biomarkers is of great significance for predicting prognosis and formulating individualized treatment plans for these patients. BRaf mutations, particularly V600E, are widely believed to be associated with poor prognosis in patients with metastatic CRC (mCRC). However, it is unclear which specific factors affect the prognosis of CRLM patients with BRaf mutations. It is also unknown whether patients with resectable CRLM and BRaf mutations should undergo surgical treatment since there is an increased recurrence rate after surgery in these patients. In this review, we combined the molecular mechanism and clinical characteristics of BRaf mutations to explore the prognostic significance and potential targeted therapy strategies for patients with BRaf-mutated CRLM.

Keywords

BRAF mutation; colorectal cancer; liver metastases; prognosis; targeted therapy.

Figures
Products